The Reality of Clinical Operations Today
Clinical development decisions require balancing incomplete safety information with multi-million dollar investment commitments. Without comprehensive external safety context, Phase 2 go/no-go decisions become high-stakes gambles rather than data-driven choices.
Incomplete Safety Context
Phase 2 go/no-go decisions made without comprehensive external safety data on comparators, class effects, and background rates. You're evaluating benefit-risk with only internal trial data while crucial context from real-world use and competitive development programs remains invisible.
Protocol Risk Blind Spots
Safety monitoring plans based on incomplete knowledge of the adverse event landscape for the target indication and population. Protocol-driven monitoring misses 70% of relevant safety signals because they weren't anticipated during protocol design.
Late-Stage Surprises
Safety signals emerging in Phase 3 that could have been anticipated with better early-phase benefit-risk analysis. Late-stage safety findings create impossible choices: halt development after hundreds of millions invested, or proceed to filing with unresolved safety concerns.
Your Workflow, Transformed
Comprehensive Safety Context Before Phase 3 Investment
Our Data Intelligence module reveals the complete safety landscape for your compound, target, and indication before you commit Phase 3 resources. We detect drug-drug interactions at 3x the rate of manual screening and identify class effects that inform protocol design and monitoring strategy.
- Background rate estimation for target population across indication, comorbidities, and concomitant medication patterns
- Class-level safety profiling identifying mechanism-based risks and adverse event patterns across therapeutic class
- Drug-drug interaction screening detecting potential DDIs at 3x manual detection rate using 100B+ real-world exposure combinations
- Comparator landscape analysis for benchmark safety profiles across approved and investigational therapies
Quantitative Go/No-Go and Protocol Optimization
Transform Phase 2 go/no-go decisions from gut-feel judgments to quantitative benefit-risk assessments. Model development scenarios, identify protocol optimizations, and build the early benefit-risk framing that will carry through regulatory interactions and commercial launch.
- Early benefit-risk framing establishing the quantitative framework before Phase 3 investment commitment
- Scenario modeling for development strategy optimization across indication expansion, combination therapy, and dosing approaches
- Quantitative go/no-go decision support with probability-weighted benefit-risk projections and Phase 3 success modeling
- Protocol safety monitoring optimization identifying high-risk subpopulations and events requiring enhanced surveillance
Development-Stage Documentation
From IND safety summaries through Investigator's Brochure updates, ArcaScience generates the safety documentation your clinical development program requires. Every document is generated from the same comprehensive data foundation, ensuring consistency across development stages.
- IND safety summaries with comprehensive class effect and DDI analysis for initial regulatory submission
- Protocol safety monitoring plans specifying event-specific surveillance based on comprehensive safety landscape analysis
- Development strategy documents supporting go/no-go decisions with quantitative benefit-risk projections
- Investigator's Brochure safety sections updated continuously as new safety data emerges during development
Impact for Clinical Operations Teams
"ArcaScience transformed our Phase 2 go/no-go process from a gut-feel decision to a quantitative benefit-risk assessment. The comprehensive safety context—including class effects, DDI screening, and comparator profiling—revealed protocol optimization opportunities we would have completely missed. We identified a critical drug-drug interaction that would have caused major issues in Phase 3, allowing us to modify our exclusion criteria before committing $200M to pivotal trials."
AstraZeneca Cardiovascular: De-Risking Phase 3 Investment with Comprehensive Safety Intelligence
AstraZeneca's cardiovascular development team used ArcaScience to inform their Phase 2 to Phase 3 transition decision for a novel anticoagulant. Comprehensive DDI screening, class-level safety profiling, and comparator analysis identified critical protocol modifications that prevented late-stage safety issues and optimized the Phase 3 monitoring strategy.
Deepen Your Understanding
Quantitative Go/No-Go: From Gut-Feel to Data-Driven Phase 3 Decisions
How leading pharma companies use comprehensive benefit-risk analysis to optimize Phase 2 to Phase 3 transitions.
Download →AI-Powered DDI Screening: 3x Detection Rate, Zero False Negatives
How machine learning analysis of 100B+ real-world exposures identifies drug interactions before clinical development.
Read →Protocol Optimization: Safety Monitoring Plans That Prevent Late-Stage Surprises
Learn how comprehensive safety intelligence informs protocol design and risk-based monitoring strategies.
Watch →